Turn Therapeutics insider increases stake to 50,734 TTRX shares

Rhea-AI Filing Summary

Turn Therapeutics Inc. (TTRX) reported an insider share purchase by a director. On 11/21/2025, the reporting person bought 20,532 shares of common stock in an open-market transaction at a weighted average price of $2.87 per share, with individual trades ranging from $2.66 to $3.25. After this transaction, the director beneficially owns 50,734 shares of common stock.

Certain shares in this total are restricted stock units (RSUs) granted under Turn Therapeutics’ 2025 Omnibus Incentive Plan, each RSU representing a right to receive one common share if vesting conditions and continued service requirements are satisfied.

Insider Trade Summary

Net Buyer: 20,532 shares ($58,927)

Net Buy 1 txn

Insider GOLDEN ARTHUR F

Role Director

Bought 20,532 shs ($59K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	20,532	$2.87	$59K

Holdings After Transaction: Common Stock — 50,734 shares (Direct)

Footnotes (1)

1. Certain of the securities reported in Column 5 of Table I are restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock, subject to the applicable vesting schedule and the reporting person's continuous service through the vesting date. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.66 to $3.25, inclusive. The Reporting Person undertakes to provide to Turn Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLDEN ARTHUR F

(Last) (First) (Middle)

C/O TURN THERAPEUTICS INC.

250 N. WESTLAKE BLVD.

(Street)

WESTLAKE VILLAGE CA 91362

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Turn Therapeutics Inc. [ TTRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/21/2025		P		20,532	A	$2.87(2)	50,734(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Certain of the securities reported in Column 5 of Table I are restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock, subject to the applicable vesting schedule and the reporting person's continuous service through the vesting date.

2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.66 to $3.25, inclusive. The Reporting Person undertakes to provide to Turn Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Zuraiz Chaudhary, attorney-in-fact for Arthur Golden	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Turn Therapeutics (TTRX) report on this Form 4?

The filing reports that a director of Turn Therapeutics Inc. (TTRX) purchased 20,532 shares of the company’s common stock in an open-market transaction.

On what date did the Turn Therapeutics (TTRX) insider purchase occur and at what price?

The purchase occurred on 11/21/2025 at a weighted average price of $2.87 per share, with individual trades executed between $2.66 and $3.25 per share.

How many Turn Therapeutics (TTRX) shares does the reporting person own after this transaction?

Following the reported transaction, the director beneficially owns 50,734 shares of Turn Therapeutics common stock.

Are any of the Turn Therapeutics (TTRX) holdings in this Form 4 restricted stock units (RSUs)?

Yes. The filing notes that certain securities included in the 50,734 shares reported are restricted stock units (RSUs) granted under the company’s 2025 Omnibus Incentive Plan.

What does each Turn Therapeutics (TTRX) RSU reported on this Form 4 represent?

Each RSU represents a contingent right to receive one share of Turn Therapeutics common stock, subject to the applicable vesting schedule and the director’s continuous service through the vesting date.

How were the Turn Therapeutics (TTRX) insider purchase prices disclosed?

The director reported a weighted average purchase price of $2.87 per share and stated that the shares were bought in multiple transactions at prices ranging from $2.66 to $3.25, and undertook to provide detailed trade information upon request.